Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Alebund Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Alebund Pharmaceuticals Raises $60 million in Series B Financing Round

              Contact the Supplier

              Lead Product(s): AP-301

              Therapeutic Area: Nephrology Product Name: AP-301

              Highest Development Status: Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Quan Capital

              Deal Size: $60 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing May 09, 2021

              Details:

              Alebund Pharmaceuticals lead product, AP-301, is a best-in-class potential in the treatment of hyperphosphatemia.

              PharmaCompass__DigitalAd